Curriculum vitae eyal Mishani

Date of Birth – 10/08/63

Work – 972-2-6777931

Email- eyalmi@ekmd.huji.ac.il

1996-2002 Medical Faculty Nuclear Medicine Lecturer

2003-2006 Medical Faculty Nuclear Medicine Senior Lecturer (with tenure)

2007- 2012 Medical Faculty Nuclear Medicine Associate Professor

2012- Medical Faculty Nuclear Medicine Professor

2. Additional function

1996- 2008 Hadassah Hospital Nuclear Medicine In charge of the cyclotron radiochemistry facility

2008- Hadassah Hospital Nuclear Medicine Director of the cyclotron radiochemistry facility

2012- IAEA Nuclear Medicine Expert

2005 - Editorial board member of Nuclear Medicine & Biology, official journal of the Society of Radiopharmaceutical Sciences.

2008- International associate editor of Molecular Imaging & Biology Journal.

2011- 2013 Director-at-Large of the Society of Radiopharmaceutical Sciences (SRS) board of directors.

2012 Nominating Committee for next election of the SRS Officers and Board members. Society of Radiopharmaceutical Sciences (SRS).

2012- Review articles subcommittee. Molecular Imaging & Biology Journal.

2013- Board member of the Society of Radiopharmaceutical Sciences (SRS).
4. International conferences

2006 Member of the scientific committee, World Congress of Nuclear Medicine and Biology (WCNMB). Seoul, Korea.

2010 Category organizer & co-chairman, PET/SPECT probes. World Molecular Imaging Conference. (2 oral sessions and 2 poster sessions about 105 abstracts in this category); Kyoto, Japan.

2011 Category organizer & co-chairman, PET/SPECT probes. World Molecular Imaging Conference. (2 oral sessions and 2 poster sessions about 130 abstracts in this category) San-Diego, USA.

2. Targetry and in target chemistry, Nuclear Research Center Negev, and prof. F. Helus.

3. A. The development of receptor radioligands for brain, heart and lung.

Prof. W. Vaalburg, Groningen university hospital.

4. Micro-PET, Prof. M. J. Welch, Washintgton University.

5. A.Clinical use of ¹⁸FDOPA & ¹¹C Choline, Prof. Fanti, University of Bologna.

6. New trends in cardiac imaging. Prof. William Strauss, Memorial Slon-Kettering, USA. Hadassah Hebrew University Hospital, Cyclotron Unit, February 2013.

7. Brain trauma and dementia: Imaging Tau pathology in living subjects. Prof. J. Barrio, David Geffen UCLA School of medicine. Israeli society of nuclear medicine conference, February 2013.

8. Monoamines and the brain at work: From experimental design to Clinical studies. Prof. D. Doudet, University of British Columbia, Canada. Israeli society of nuclear medicine conference, February 2013.

6. Grants.

1999 International Atomic Energy Agency Grant, National and regional production of fluorinated radiopharmaceuticals – clinical and scientific aspects. R. Chisin, E. Mishani.

1999-2002 Binational Science Foundation (BSF), Labeled PET tracers for EGFr-TK and estrogen receptors. E. Mishani (PI).

2001-2002 Israel Cancer Association, Evaluation of prostate cancer with PET using [C-11]choline. M. Bocher, E. Mishani, R. Chisin.

2001-2007 A start-up company was established for research on EGFR, Hadassah-Hebrew University -Naiot. (with Prof. A. Levitzki)

2003-2007 NIH, Functional dopamine neurons from human ES cells.

Reubinoff Benjamin (PI), Ben Hur Tamir (Co-Investigator), Bergman Hagi (Co-Investigator), Mishani Eyal (Co-Investigator), Segal Menahem (Co-Investigator).

2005-2008 Joint German-Israeli Research Program, Development and clinical application of a PET-SERT ligand labeled with fluorine-18. Eyal Mishani (PI), Roland Chisin (Co-PI) Joerge Stainbach (Co-PI).

2007-2008 Aposense Inc.- Development the labeling and purification of ML-10, A potential PET imaging agent for apoptosis. Eyal Mishani (PI).

2007-2010 Israel Science Foundation (ISF), Targeting the Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) in cancer - Development of PET molecular imaging agents. Eyal Mishani (PI).

2008-2010 Pain Therapeutics Inc.- Labeling development (Tc-99m and Re-188), purification and evaluation, in melanoma mice model, of novel melanin selective IgGs. Eyal Mishani (PI).

2010-2011 TEVA Inc. – Development the radiolabeling of Laquinimod, a novel drug for the treatment of Multiple-Sclerosis, and investigation of Laquinimod’s distribution in healthy and diseased mice by micro-PET/CT. Eyal Mishani (PI) and Galith Abourbeh (Co-PI).

2011-2011 Aposense Inc. - F-18 ML10 Micro-PET studies in apoptotic animal model. Galith Abourbeh (PI), Eyal Mishani (Co-PI).

2011-2014 Israel Science Foundation (ISF), Carbon-11/Fluorine-18 labeled ammonium salts as myocardial perfusion PET imaging agents. Eyal Mishani (PI), Galith Abourbeh, Haim Danenberg, Moshe Bocher.

1. S. Rozen, E. Mishani and M. Kol (1991). A novel electrophilic methoxylation (with a little help from F₂). J. Am. Chem. Soc. 114: 7643-7645.

2. E. Appelman , D. French, E. Mishani and S. Rozen (1993). Synthesis, characterization, and reaction chemistry of tert-butyl hypofluorite. J. Am. Chem. Soc. 115: 1379-1382.

3. S. Rozen, E. Mishani (1993). Conversion of esters to -difluoro ethers using BrF₃. J. Chem. Soc. Chem. Commun. 1761-2.

4. S. Rozen, A. Bar Haim and E. Mishani (1994). A new efficient route to  nitro acids. oxidation of amino acids with HOF^.CH₃CN. J. Org. Chem. 59: 1208-9.

5. S. Rozen, E. Mishani, I. Ben-David and M. Kol (1994). The chemistry of methyl hypofluorite with various unsaturated centers. J. Org. Chem. 59: 4281-4284.

6. S. Rozen, E. Mishani, A. Bar-Haim (1994). A novel carbonyl to CF₂ transformation using BrF₃. J. Org. Chem. 59: 2918.

7. S. Rozen, A. Bar-Haim and E. Mishani (1994). Fluorination of nitro compounds with acetyl hypofluorite. J. Org. Chem. 59: 6717.

8. S. Rozen, E. Mishani (1994). A novel method for converting aromatic acids into trifluoromethyl derivatives using BrF₃. J. Chem. Soc. Chem. Commun. 2081.

9. E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1995). A study of - trifluoro toluenes mediated [¹⁸F] fluoro - for - nitro exchange. A useful intermediate in the synthesis of highly fluorinated radiopharmaceuticals. J. Labl. Comp. Radiopharm. 37: S575-7.

10. C. S. Dence, E. Mishani, T. J. McCarthy, M. J. Welch (1995). Evaluation of a microwave cavity for the synthesis of PET radiopharmaceuticals. J. Labl. Comp. Radiopharm. 37: S115-6.

11. S. Rozen, Y. Bareket, I. Ben-David and E. Mishani (1995). The impact of F₂ on organic chemistry. J. Labl. Comp. Radiopharm. 37: S641-3.

12. E. Mishani, C. S. Dence, T. J. McCarthy and M. J. Welch (1996). Formation of phenylpiperazines by a novel alumina supported bis-alkylation. Tet. Lett. 37: 319-322.

13. E. Mishani, R. M. Brodbeck, J. E. Krause, C. S. Dence, T. J. McCarthy and M. J. Welch (1997). Synthesis and evaluation of A fluorine-18 labeled NK-1 antagonist. J. Labl. Comp. Radiopharm. 40: S653–655.

14. E. Mishani, Michael E. Cristel, Carmen S. Dence, Timothy J. McCarthy, Michael J. Welch (1997). Application of a novel phenylpiperazine formation reaction to the radiosynthesis of ¹⁸FTFMPP, a potent serotonin agonist. J. Nucl. Med. Biol. 24: 269-273.

15. I. Ben-David, E. Mishani, S. Rozen (1998). tert-Butyl Hypofluorite - an electrophilic tert-butoxylation agent. J. Org. Chem. 63: 4632.

16. E. Mishani, N. Lifshits, A. Osavistky , J. Kaufman, N. Ankry, N. Tal, R. Chisin (1999) .Radiation levels in cyclotron-radiochemistry facility measured by a novel comprehensive computerized monitoring system. Nucl. Instr. Meth. Phys. Res. A, 425: 332-342.

17. E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki (1999). Fluorinated EGFR-TK inhibitor-based tracers for PET. J. Labl. Comp. Radiopharm. 42: S27-29.

18. I. Ben David , D. Rechavi, E. Mishani , S. Rozen (1999). A Novel synthesis of trifluoromethyl ethers via xanthates, utilizing BrF₃. J. Fluorine Chem. 97: 75-78.

19. M. Klein, N. Freedman, E. Mishani, Z. Gimon, M. Lotem, R. Chisin (2000). PET and lymphoscintigraphic evaluation of malignant melanomas. Nuklear Medizin, 39: 56-61.

20. M. Bocher, E. Mishani (2000). The contribution of Positron Emission Tomography-PET to patient management in oncology. J. of the Israel Medical Association. 139: 64-67.

21. T. A. Bonasera, G. Ortu, Y. Rozen, R. Krais, N. M.T. Freedman, R. Chisin, A. Gazit, A. Levitzki and E. Mishani (2001). Potential ¹⁸F-labeled biomarkers for Epidermal Growth Factor Receptor Tyrosine Kinase. J. Nucl. Med. Biol. 28: 359-37.

22. E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki (2001). Carbon-11 labeled irreversible inhibitors for mapping Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK). J. Labl. Comp. Radiopharm. 44: S94-96.

23. E. Mishani, I. Ben David (2001). [C-11] Acryloyl chloride- a fully automated preparation and reaction with model amine. J. Labl. Comp. Radiopharm. 44: S475-476.

24. E. Mishani, I. Ben-David, Y. Rozen, D. Laki, M. Bocher, R. Chisin (2001). [C-11]Choline - automated preparation and clinical utilization. J. Labl. Comp. Radiopharm. 44: S379-381.

25. M. Bocher, R. Chisin, Y. Parag, N. Freedman, Y. Meir, H. Lester, E. Mishani, O. Bone (2001). Cerebral activation associated with sexual arousal in response to a pronographic clip: A [O-15]water PET Study in heterosexual men. Neuroimage, 14: 105-117.

26. G. Ortu, I. Ben-David, Y. Rozen, A. Levitzki, E. Mishani (2001). Biological evaluation of a novel C-11 labelled irreversible EGFRTK inhibitor. Quar. J. Nucl. Med. 45: S7.

27. E. Mishani, I. Ben-David, Y. Rozen (2002). Improved method for the quality assurance of [C-11]choline. J. Nucl. Med. Biol. 29: 359-362.

28. G. Ortu, I. Ben-David, Y. Rozen, N. M. Freedman, R. Chisin, A. Levitzki, E. Mishani (2002). In-vitro and In-vivo investigation of an irreversible labeled EGFR inhibitor (ML03) and its potential as PET biomarker in cancer and feasibility as an anticancer drug. Int. J. of Cancer, 101: 360-37.

29. I. Ben-David, Y. Rozen, G. Ortu, E. Mishani (2003). Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [C-11]Acryloyl chloride. Appl. Rad. Isotp. 58: 209-217.

30. E. Even-Sapir, U. Metser, G. Flusser, L. Zuriel, Y. Kollender, H. Lerman, G. Lievshitz, I. Ron, E. Mishani (2004). Assessment of malignant skeletal disease:  Initial experience with 18F-Fluoride PET/CT and comparison between 18F-Fluoride PET and 18F-Fluoride PET/CT. J. Nuc. Med. 45: 272-278.

31. E. Mishani, G. Abourbeh, Y. Rozen, O. Jacobson, D. Laky, I. Ben David, A. Levitzki, M. Shaul (2004). Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. J. Nucl. Med. Biol. 31: 469-476.

33. Y. Barda, N. Cohen, V. Lev, N. Ben-Aroya, Y. Koch, E. Mishani, M. Fridkin, C. Gilon (2004). Backbone metal cyclization: novel ^99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer. J. Nucl. Med. Biol. 31: 921-933.

35. 
    N. M. T Freedman, E. Mishani, Y. Krausz, J. Weininger, H. Lester, E. Blaugrund, D. Ehrlich, R. Chisin (2005). In-vivo measurement of brain Monoamine Oxidase B (MAO-B) occupancy by Rasagiline, using 11C-L-Deprenyl and Positron Emission Tomography (PET). J. Nuc. Med. 46: 1618-1624. 35.
    
36. 
    E. Mishani, G. Abourbeh, O. Jacobson , M. Shaul, R. Ben-Daniel , S. Dissoki, Y. Rozen, A. Levitzki (2005). High affinity EGFR irreversible inhibitors with diminished chemical reactivities as PET- imaging agent candidates of EGFR over-expressing tumors. J. Med. Chem. 48: 5337-5348.
    

38. E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, I. Leibovitch (2006). The detection of bone metastases by ^99mTC-MDP planar bone scintigraphy, single and multi-field-of-views SPECT, ¹⁸F-fluoride PET and ¹⁸F-fluoride PET -CT. Prospective study in 44 patients with high risk prostate cancer. J. Nuc. Med. 47: 287-297.

39. O. Wald, I. D. Weiss, H. Wald, H. Shoham, Y. Bar-Shavit, K. Beyder, E. Galun, L. Weiss, L. Flaishon , I. Shachar, A. Nagler, B. Lu, C. Gerard, J.L. Gao, E. Mishani, J. Farber, and A. Peled (2006). IFN- acts on T cells to induce NK cell mobilization and accumulation in target organs. J. Immunol. 176 (8): 4716-29.

40. S. Dissoki, D. Laky, E. Mishani (2006). Fluorine-18 labeling of ML04 – presently the most promising irreversible inhibitor candidate for visualization of EGFR in cancer. J. Labl. Comp. Radiopharm. 49 (6): 533-543.

42. A. Levitzki and E. Mishani (2006). Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75: 93-109.

45. S. Dissoki, Y. Aviv, D. Laky, G. Abourbeh, A. Levitzki and E. Mishani (2007). The effect of the [¹⁸F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-yl]-amide moiety – an EGFR putative irreversible inhibitor. Appl. Rad. Isotp. 65: 1140-1151.

47. E. Mishani, G. Abourbeh (2007). Cancer molecular imaging: Radionuclide-Based biomarkers of the Epidermal Growth Factor Receptor (EGFR). Curr. Top. Med. Chem. 7 (18): 1755-1772.

48. O. Jacobson, E. Mishani (2008). [¹¹C]-Dimethylamine as a labeling agent for PET biomarkers. Appl. Rad. Isotp. 66: 188-193.

49. A Bar-Haim Erez , N. Freedman , N. Katz , O. Abramsky , E. Mishani, R. Chisin (2008). Neural mechanism of visual attention in unilateral spatial neglect following stroke: A preliminary PET study. Israeli Journal of Occupational Therapy. 17(1), E3-22.

50. O. Ilovich, O. Jacobson, Y. Aviv (S), A. Litchi, R. Chisin, E. Mishani. (2008). Formation of fluorine-18 labeled diaryl ureas-labeled VEGFR-2/PDGFR dual inhibitors as molecular imaging agents for angiogenesis. Bioorg. Med. Chem. 16: 4242-4251.

51. R. Ben Daniel, W. Deuther-Conrad, M. Scheunemann, J. Steinbach, P. Brust, E. Mishani. (2008). Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg. Med. Chem. 16: 6364-6370.

52. E. Mishani, G. Abourbeh, M. Eiblmaier and C. J. Anderson (2008). Imaging of the EGFR and EGFR tyrosine kinase overexpression in tumors. Curr. Pharm. Design,14 (28): 2983-2998

53. S. Dissoki, R. Eshet, H. Billauer, E. Mishani. (2009). Modified PEG-anilinoquinazoline derivatives as potential EGFR PET agents.  J. Labl. Comp. Radiopharm. 52: 41-52.

54. O. Ilovich, O. Åberg, B. Långström and E. Mishani. (2009). Rhodium-mediated [¹¹C]Carbonylation: A library of N-Phenyl-N’-{4-(4-quinolyloxy)-phenyl}-[¹¹C]-urea derivatives as potential PET angiogenic probes. J. Labl. Comp. Radiopharm. 52: 151-157.

55. I. Ruvinsky , M. Katz, A. Dreazen, Y. Gielchinsky, A. Saada , N. Freedman, E. Mishani, G. Zimmerman, J. Kasir, O. Meyuhas. (2009). Mice deficient in ribosomal protein S6 phosphorylation suffer from muscle weakness that reflects a growth defect and energy deficit. PLoS ONE, 2009 May 19;4(5):e5618.

56. E. Afergan, H. Epstein, N. Koroukhov, M. Klein, A. Litchi, E. Mishani, G. Golomb. (2009). Biodistribution and Imaging studies of ⁶⁷Ga-Labeled Liposomes in Rabbits with a Vascular Injury. J. Drug Deliv. Sci. Tec. 19: 263-268.

57. E. Mishani, A. Hagooly (2009). Strategies for molecular imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in cancer. J. Nuc. Med. 50 (8):1199-1202

58. MA. Pantaleo, E. Mishani, C. Nanni, L. Landuzzi , S. Boschi, G. Nicoletti, S. Dissoki, P. Paterini, PP. Piccaluga , F. Lodi, PL. Lollini , S. Fanti and G. Biasco. (2010). Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol. Imaging Biol. 12 (6): 616-625.

59. O. Ilovich, H. Billauer, S. Dotan and E. Mishani. (2010). Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers. Bioorg. Med. Chem. 18 (2): 612-620.

60. O. Cohen, E. Mishani, S. Rozen. (2010). From carboxylic acids to the trifluoromethyl group using BrF3. Tetrahedron, 66: 3579–3582.

61. O. Ilovich, H. Billauer, S. Dotan, N. M.T. Freedman, M. Bocher, and E. Mishani (PI). (2011). Novel and simple carbon-11 labeled ammonium salts as PET agents for myocardial perfusion imaging. Mol. Imaging Biol. 13: 128-139.

62. Y. Krausz , N. Freedman, R. Rubinstein, E. Lavie, M. Orevi, S. Tshori , A.Salmon , B. Glaser, R. Chisin, E. Mishani, DJ. Gross . (2011). 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-Octreotide (OctreoScan®). Mol. Imaging Biol. 13: 583-593.

63. F. Wolfhagen Sand, A. Hornblad , JK. Johansson, C. Loren, J. Edsbagge, J. Magenheim, O. Ilovich, E. Mishani , Y. Dor, U. Ahlgren , H. Semb . (2011). Growth-limiting role of endothelial cells in endoderm development. Dev. Biol. 352: 267-277.

64. A. Lazarus, PM. Del-Moral, O. Ilovich, E. Mishani, D. Warburton, and E. Keshet. (2011). A perfusion-Independent role of blood vessels in patterning branching stereotypy of mouse lung airway. Development, 138: 2359-2368.

65. S. Dissoki, A. Hagooly, S. Elmachily, E. Mishani (2011). Labelling approaches for the GE11 peptide - an EGFR biomarker. J. Labl. Comp. Radiopharm. 54: 693-701.

66. J. Magenheim, O. Ilovich, A. Lazarus, A. Kolchendler, O. Ziv, R. Werman, A. Hija, O. Cleaver, E. Mishani, E. Keshet, Y. Dor. (2011). Blood vessels restrain bracnching, differentiation and growth. Development, 138: 4743-4752.

67. A. Gruzman, A. Elgart, O. Viskind, H. Billauer, S. Dotan , G. Cohen , E. Mishani, A. Hoffman, E. Cerasi , S. Sasson (2012). Antihyperglycaemic activity of a lipophilic pentose derivative intype-1 and type-2 diabetic mice. J. Cell. Mol. Med. 16: 594-604.

68. Y. Krausz, R. Rubinstein , L. Appelbaum, E. Mishani, M. Orevi , M. Fraenkel, S. Tshori, B. Glaser, M. Bocher, A. Salmon, R. Chisin , DJ. Gross , N. Freedman . (2012). Ga-68 DOTA-NOC uptake in the pancreas: Pathological and physiological patterns. Clin. Nucl. Med. 37 (1): 57-62.

69. O. Ilovich, G. Abourbeh, M. Bocher, N. Freedman, H. Billauer, S. Dotan, H. D. Danenberg and E. Mishani. (2012). Structure-activity relationship and preclinical evaluation of carbon-11-labeled ammonium salts as PET-myocardial perfusion imaging agents. Mol. Imaging Biol. 14: 625-636.

70. M. Orevi, M. Klein, E. Mishani, R. Chisin, N. Freedman, O. N. Gofrit. (2012). C-11 acetate PET/CT in bladder urothelial carcinoma: Intraindividual comparison with C-11 choline. Clin. Nucl. Med. 37 (4): e67-72.

71. G. Abourbeh , A. Shir, E. Mishani, M. Ogris, W. Rödl, E. Wagner and A. Levitzki. (2012). PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life, 64 (4): 324-330.

72. AL. Kesner, G. Abourbeh, E. Mishani, R. Chisin, S. Tshori and N. Freedman. (2013). Gating, enhanced gating, and beyond: information utilization strategies for motion management, applied to preclinical PET. Eur. J. Nucl. Med. Mol. I. Res. 3 (1): 1-15.

73. V. Kepe, M.C. Moghbel, B. Langstrom, H. Aaidi, H. V. Vinters, S.C. Huang, N. Satyamurthy, D. Doudet, E. Mishani, R. M. Cohen, P. F. Hoilund-Carlsen, A. Alavi, J. R. Barrio. (2013). Amyloid-β Positron Emission Tomography Imaging Probes: A Critical Review. J Alzheimers Dis. 36 (4):613-631.

74. Jacobson O., Abourbeh G., Tsvirkun D., Mishani E. (2013). Rat Imaging and In Vivo Stability Studies using [11C]-Dimethyl-Diphenyl Ammonium, a Candidate Agent for PET-Myocardial Perfusion Imaging. J. Nucl. Med. Biol. In Press.

Patents

1. E. Mishani, T. A. Bonasera, Y. Rozen, G. Ortu, A. Gazit, A. Levitzki. Novel Epidermal Growth Factor Receptor-Kinase Binding Compounds for Positron Emission Tomography.

2. E. Mishani, I. Ben David, Y. Rozen, G. Ortu, A. Levitzki, Radiolabeled inhibitors for Epidermal Growth Factor Receptor Tyrosine Kinase and their use in radioimaging and radiotherapy.

4. S. Dissoki, G. Abourbeh, A. Levitzki, E. Mishani. Labeled EGFR irreversible biomarkers: Anilinoquinazoline-7-[F-18]-PEG derivatives.

5. E. Mishani, O. Jacobson. ¹¹C and ¹⁸F- labeled Androgen-Receptor (AR) ligands for use in the treatment and diagnosis of AR-related pathologies.

6. E. Mishani, Y. Rozen, G. Abourbeh, A. Levitzki. Novel EGFR-TK irreversible inhibitors for cancer therapy, radiotherapy and diagnosis.

7. E. Mishani, H. Billauer, G. Abourbeh, S. Dotan, N. M.T. Freedman, H. Danenberg, M. Bocher. Ammonium salt for myocardial perfusion imaging.

1. Alkylhypofluorite and electrophilic fluorination, Corporate science and technology center, Air Products and Chemicals, USA, 1996.

2. Positron Emission Tomography - overview, Nuclear Research Center – Sorek, Israel, 1998.

3. Positron Emission Tomography - overview, Nuclear Research Center – Negev, Israel, 1998.

4. PET-Oncology, [C-11]Choline and EGFR labeled inhibitors, Tel Aviv University, School of Chemistry, 2001.

5. The inter-phase, nuclear physics-nuclear medicine. Mini-seminar, The Israeli pharmacist organization, Health Ministry. Sorasky Medical Center, Tel Aviv, 2003.

6. Direct labeling of Tyrosine Kinase ligands. Work-shop; Modern imaging technology, Annual Conference of the Society of Nuclear Medicine, New Orleans, USA, 2003. Invited lecture.

7. PET molecular imaging of angiogenesis and gene therapy. Rambam Hospital & Rapaport Institute, Haifa, Israel, 2004.

8. Labeled molecular imaging agents of the EGFR-TK for specific in-vivo diagnostic and, image guided treatment of cancer. Bioorganic Chemistry. The 69^th Meeting of the Israel Chemical Society, Tel Aviv, Israel, 2004.

9. PET radiopharmaceuticals for oncology. Rambam Hospital & Rapaport Institute, Haifa, Israel, 2004.

10. Animal-PET and Micro-PET molecular imaging. Imaging in laboratory animals- experimental approaches and techniques. Hebrew University/Hadassah Hospital. The Authority for Animal Facilities, Israel, 2005.

11. Visualizing EGFR in cancer. Azienda Ospedaliera S.Orsola-Malpighi University Hospital. Bologna, Italy. 2005

12. Receptor based molecular imaging in oncology. New trends in molecular imaging and nuclear medicine. Annual Conference at the University of Bologna Italy. 2006

13. PET imaging bioprobes in oncology: design, labeling and preclinical studies. Department of Biological Regulation, Weizmann Institute of Science, Israel 2007.

14. PET bioprobes for molecular imaging. Hybrid imaging (PET/CT) symposium, Philips. Israel 2007.

15. Personalized medicine: Image guided treatment. Israel Medical Convention, Jerusalem, Israel 2007.

16. 
    PET radiopharmaceuticals production and clinical application. Soreq Nuclear research center, Israel, 2008.
    
17. 
    Development of radiolabeled inhibitors of EGFR and VEGFR Tyrosine Kinases as PET agents. "Molecular imaging for better diagnosis and management of diseases" Bayer Healthcare, Bayer Schering pharma, Life Sciences Workshop Series, Berlin, Germany, 2008.
    
18. 
    PET isotopes and radiopharmaceuticals: production and clinical application. Symposium honoring the 90^th birthday of Prof. Israel Dostrovsky; Outward Bound: From nuclear chemistry to solar neutrinos. Weizmann Institute of Science, Israel 2008.
    
19. 
    Novel PET tracers for imaging of cancer patients. Annual Conference of the European Organization for Research and Treatment of Cancer, Radiation Oncology Group (EORTC-ROG), Haifa, Israel, 2009.
    
20. 
    PET Biomarkers for molecular imaging. BIT’s 1^st Annual Tera-congress of molmed, Shanghai China, 2010.
    
21. 
    PET molecular imaging agents – labeled magic bullets. Rambam Hospital, Haifa, Israel, 2010.
    
22. 
    PET molecular imaging agents in oncology and cardiology, Albert Einstein Hospital, Sao Paulo, Brazil. 2011.
    
23. 
    Strategies for molecular imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in cancer. New Frontiers in Molecular Imaging and Therapy Conference, National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand.2011.
    
24. 
    Tracers beyond FDG: New magic bullets. New Frontiers in Molecular Imaging and Therapy Conference, National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand. 2011.
    
25. 
    PET molecular imaging in oncology and cardiology, The Racah Inst. of Physics, Hebrew University, Jerusalem, Israel.2012.
    
26. 
    PET molecular imaging in oncology and cardiology, Tel Aviv University, School of Chemistry, Tel Aviv, Israel. 2012.
    
27. 
    Sustaining proliferative signaling, Imaging Sigmal transduction in Cancer, The 7^th ESMI Winter conference - Hot Topic in molecular Imaging: Imaging Hallmark of Cancer, France, 2013.
    
28. 
    PET molecular imaging in oncology and cardiology, Bar-Ilan University, School of Chemistry, Tel Aviv, Israel. 2013.
    
29. 
    PET MPI imaging agents, International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC 2013). International Atomic Energy Agency, Vienna, Austria. 2013.
    
30. 
    The quality control Process of MPI Agents, International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC 2013). International Atomic Energy Agency, Vienna, Austria. 2013.